



10 February 2014

## **Pharmacelsus and Insilico Biotechnology join forces to deliver combined solutions in preclinical drug development**

**(Stuttgart/Saarbrücken) – Pharmacelsus, Germany's market-leading preclinical CRO and Insilico Biotechnology, leading provider of innovative solutions around the simulation of biological processes, combine their expertise in preclinical characterization of drug-candidates.**

The two companies' new joint service exploits Pharmacelsus' experimental expertise and Insilico's skills in the fields of modeling and simulation, yielding end-to-end solutions for the testing of potential drugs. During the process, a minimum amount of empirical *in vitro* data is generated. These data are then evaluated using computational models in order to predict the effects of the API on the human body or the outcome of preclinical animal trials with high accuracy. The integrated approach reduces the required experimental effort, particularly in animal testing, simplifies the selection of promising drug candidates, and reduces risk, time, and cost of the drug development process.

The combined portfolio includes the prediction of pharmacokinetic properties and equivalent *in vivo* doses both in preclinical species and in humans on the basis of *in vitro* ADMET data. This allows customers to develop the optimal protocol for necessary animal studies. Additionally, customer's challenging problems in research can be tackled applying the integrated knowledge base in preclinical drug development, bioanalytics, modeling and simulation.

"The alliance with Pharmacelsus enables Insilico to offer new packages comprising experimental services and simulation solutions. Pharmacelsus is the ideal partner for this joint enterprise", said Klaus Mauch, CEO of Insilico. Dr. Christine Batzl-Hartmann, Pharmacelsus' CEO, added: "We are glad about the fact that the long-standing cooperation between Pharmacelsus and Insilico will now mount a combined service, and we are confident that this service will provide an aid in our customers' preclinical research."

**Insilico Biotechnology** is a market-leading company providing solutions and software for the simulation of living cells. An interdisciplinary team of experts offers customised solutions for the efficient manufacturing of biotechnological products and for the testing of pharmaceuticals by using high-performance computing and Insilico's proprietary software platform. For world-leading companies from the chemical and pharmaceutical industries, Insilico's technology lowers time, risk and costs of development processes. Founded in 2001, Insilico is a privately held company based in Stuttgart, Germany. For further information, please visit [www.insilico-biotechnology.com](http://www.insilico-biotechnology.com).

**Pharmacelsus** is an independent contract research organization (CRO) based in Saarbrücken, Germany. It offers preclinical services in the fields of biology, pharmacology and analytics. Over the past years, Pharmacelsus has gained one of the leading positions among German CROs and employs its expertise for the benefit of an

# Press Release



international customer base comprised of pharmaceutical and biotechnological companies. Since 2008, it holds a GLP (Good Laboratory Practice) certification. The company also performs complementary services for clinical studies (GCLP) in addition to its preclinical portfolio. For further information, please visit [www.pharmacelsus.com](http://www.pharmacelsus.com).

## **Contact:**

Insilico Biotechnology AG  
Dr. Bettina Stahnke | Business Development  
T +49 711 460 594-30  
F +49 711 460 594-10  
[bettina.stahnke@insilico-biotechnology.com](mailto:bettina.stahnke@insilico-biotechnology.com)

Pharmacelsus GmbH  
Dr. Christine Batzl-Hartmann | CEO  
T +49 681 3946-7510  
F +49 681 3946-7511  
[batzl@pharmacelsus.de](mailto:batzl@pharmacelsus.de)